– The 28 systems that will be deployed in the three KRC laboratories will test around 94% of the country’s blood donation
– They will run the Procleix Ultrio Elite Assay, an advanced nucleic acid test (NAT) that ensures donation safety by detecting the potential presence of the most important infectious pathogens in a single concurrent test.
– Grifols recently expanded its excellence in blood safety to the region, with more countries trusting it to protect their blood supplies
Barcelona, Spain, June 3, 2021 / PRNewswire / – Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and innovative diagnostic solutions, today announced that it will provide the Korean Red Cross (KRC) with its state-of-the-art Procleix Panther system running nucleic acid testing (NAT) technology to help ensure the safety of South Korea blood supply.
Under the KRC contract, Grifols will supply 28 Procleix Panther systems to be deployed over the next few months at the humanitarian organization’s three laboratory sites in South Korea. When fully operational, they will test around 94% of the country’s donated blood, which is mostly needed for transfusions.
Procleix Panther systems are known for their reliability, scalability and versatility, delivering high throughput with a small footprint while streamlining laboratory workflow. They will include the Procleix Ultrio Elite Assay, a high specificity NAT designed to improve blood safety by detecting the potential existence of the most important infectious pathogens in a single simultaneous assay from human serum or plasma.
“More and more countries in Asia Pacific rely on the innovative, robust and efficient screening capabilities of the Procleix Panther system to protect their blood supply, ”said David Rosée, president of the commercial division of Grifols Diagnostic. “The combination of quality, safety and advanced technology from Grifols makes an important difference in improving the health and well-being of patients.”
Grifols has steadily increased its leadership in blood safety in Asia Pacific, where it currently screens more than half of all donated blood, including 100% of those donated Australia, Japan, Malaysia and New Zealand.
Grifols Korea, formed in 2020, is the company’s newest subsidiary in Asia Pacific, where it grew to 13 subsidiaries after establishing its first presence in the region in 2000. China, where Grifols has a strategic alliance with Shanghai RAAS, a leader in the country’s plasma derivatives industry, is one of the company’s most important markets for the sale of Procleix NAT solutions.
About the Procleix Panther System
The Procleix Panther system automates all aspects of NAT (nucleic acid testing) based blood screening on a single integrated platform and is capable of delivering the highest throughput of results per square meter. It eliminates the need for batch processing and combines walking freedom with an intuitive design for easy operation.
About Procleix NAT Solutions
Today, Procleix systems are used to screen more donated blood globally than any other NAT blood screening product, and include testing for HIV, hepatitis viruses (A, B, C and E ), West Nile virus, SARS-CoV-2 *, Zika virus, dengue virus, Babesia, and more.
About the Procleix Ultrio Elite test
The Procleix Ultrio Elite assay is a nucleic acid assay (NAT) that uses magnetic target capture, transcription-mediated amplification (TMA) and chemiluminescence to detect HIV-1, HIV-2, HBV and HCV in donated blood serum or plasma. . Due to the high sensitivity and specificity of the technology, detection of targeted pathogens can be achieved in the early stages of infection, thus helping to prevent transfusion of infected blood or blood components even when the donor is not presents no symptoms and traditional serological screening techniques do not allow detection of the presence of the pathogen or of the antibodies directed against it. The assay runs on the Procleix Panther system, a fully automated NAT instrument launched by Grifols in the EU market in 2012 and currently widely used in laboratories around the world.
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostics, Hospital and Bio Supplies – develop, produce and market innovative solutions and services which are sold in more than 100 countries.
Pioneers in the plasma industry, Grifols operates a growing network of donation centers around the world. It transforms the collected plasma into essential medicines to treat chronic, rare and sometimes fatal conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to improve the safety of donation to transfusion. In addition, the company provides tools, information and services that enable hospitals, pharmacies and healthcare professionals to effectively deliver specialized medical care.
Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.
In 2020, Grifols’ economic impact in its main countries of operation was 7.5 billion euros. The company has also generated 140,000 jobs, including indirect and induced.
The company’s Class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Grifols Class B non-voting shares are listed on the Mercado Continuo (MCE: GRF.P) and on the US NASDAQ via ADRs (NASDAQ: GRFS).
For more information, please visit www.grifols.com
*In development. Performance characteristics have not been established.
Facts and figures contained in this report which do not refer to historical data are “future projections and assumptions”. Words and phrases such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated “,” to come “and similar expressions, as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, assumptions, expectations and forecasts of the management team at the time of writing, and these are subject to a number of factors which mean that actual results may differ materially. The future results of the Grifols group could be affected by events related to its own activities, such as a disruption in the supply of raw materials for the manufacture of its products, the appearance of competing products on the market, or changes in the market. regulatory framework of the markets in which it operates, among others. At the time of writing this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, SA accepts no obligation to publish, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing of this report, unless expressly required by applicable law. . This document does not constitute an offer or an invitation to buy or subscribe for shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving the recast text of the Securities Market Law movable; Royal decree law 5/2005, of March 11 and / or Royal decree 1310/2005, of November 4, and any regulation developing this legislation. In addition, this document does not constitute an offer to buy, sell or exchange, nor a request for an offer to buy, sell or exchange securities, nor a request for a vote or approval in any other jurisdiction. The information contained in this document has not been verified or reviewed by the external auditors of the Grifols group.